ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

SAN DIEGO , Oct. 30, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced the extension of its Chemistry, Manufacturing and Controls (CMC) services collaboration supporting the clinical development of ratutrelvir, a promising oral antiviral treatment for COVID-19. The announcement follows recent progress by Traws Pharma, Inc. (NASDAQ: TRAW), which dosed the first patient in Phase 2 studies of ratutrelvir in October 2025, with top-line data expected by year-end 2025.

Ratutrelvir, a ritonavir-free Main protease (Mpro/3CL) inhibitor, was discovered and developed ab initio from target to clinic by ChemDiv's medicinal chemistry and virology services teams. Leveraging Molsoft's rational drug design platform and Expert Systems' predictive